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Abstract
Background:  Over the past decade pediatric bipolar disorder has gained recognition as a
potentially more severe and heritable form of the disorder. In this report we test for association
with genes coding brain-derived neurotrophic factor (BDNF), the serotonin transporter (SLC6A4),
and catechol-O-methyltransferase (COMT).
Methods: Bipolar-I affected offspring triads (N = 173) were drawn from 522 individuals with 2
parents in 332 nuclear families recruited for genetic studies of pediatric psychopathology at the
Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at
Massachusetts General Hospital.
Results: We failed to identify an association with the val66 allele in BDNF (OR = 1.23, p = 0.36),
the COMT-l allele (OR = 1.27, p = 0.1), or the HTTLPR short allele (OR = 0.87, p = 0.38).
Conclusion: Our study suggests that the markers examined thus far in COMT and SLC6A4 are not
associated with pediatric bipolar disorder and that if the val66met marker in BDNF is associated
with pediatric bipolar disorder the magnitude of the association is much smaller than first reported.
Background
Several lines of evidence suggest that the age at onset of
bipolar disorder may be a potentially important marker of
a more severe and more familial form of the disorder.
Consistent with the clinical observations made by Carlson
et al [1] 25 years ago, the current literature suggests that
pediatric bipolar disorder is associated with severe impair-
ment, rapid cycling, early age at onset and significant psy-
chiatric comorbidity. The presentation of bipolar disorder
in children is not unlike that described in adults as mixed
mania by McElroy et al [2]: a rapid-cycling and recurrent
disorder with poor inter-episode functioning, frequent
onset in childhood and adolescence, a high risk of suicide,
high risk of substance use disorders, poor response to
treatment, a history of poor school performance, and neu-
ropsychological deficits highly suggestive of attention-def-
icit/hyperactivity disorder [3-11].
Studies of adult subjects with bipolar disorder strongly
suggest a genetic component in etiology of the disorder.
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Twin studies [12-17] suggest heritability estimates from
79% to 93% for mania/bipolar disorder. Smoller and
Finn [18] estimated a 10-fold increase in the recurrence
risk (8.7%) for bipolar disorder among first-degree rela-
tives of bipolar probands. Likewise, an excess recurrence
risk of bipolar disorder has been reported in family stud-
ies of affected child probands utilizing DSM-III [19-22],
DSM-IIIR [23], and DSM-IV [6,8,10,24] criteria for bipo-
lar disorder. The recurrence risks reported in the pediatric
literature (12–35%) are considerably higher than esti-
mates of the risk for bipolar disorder in the relatives of
adult probands (5–10%) [18,25].
Despite the evidence documenting that early-onset of
bipolar disorder increases the familial recurrence rate,
there has been very little molecular genetic research
focused on pediatric bipolar disorder. Each of the candi-
date genes examined for association with pediatric bipolar
disorder were selected largely because they are involved
with neurotransmitter systems hypothesized to be altered
in mood disorders based upon pharmacological response
or animal models. However, only five genes have been
examined and four of the available reports come from a
single sample of approximately 50 families at Washington
University [26-29].
The serotonin transporter is a monoamine transporter
protein that transports serotonin from synaptic spaces
into presynaptic neurons. A 44-bp variable-number tan-
dem-repeat (VNTR) polymorphism in the in the promoter
region (HTTLPR) of the serotonin transporter gene
(SLC6A4) influences the transcription and function of the
transporter [30]. Geller et al [26] found no evidence of
association with the serotonin transporter gene (SLC6A4)
at the HTTLPR locus (i.e. a 44-bp VNTR in the promoter)
in 46 affected offspring trios.
Catechol-O-methyltransferase (COMT) catalyzes the
transfer of a methyl group from S-adenosylmethionine to
catecholamines, including the neurotransmitters
dopamine, epinephrine, and norepinephrine [31]. A vari-
ant caused by a G-to-A transition at codon 158 of the
COMT gene, results in a valine-to-methionine substitu-
tion [32]. Homozygosity for 158met leads to a 3- to 4-fold
reduction in enzymatic activity, compared with homozy-
gosity for 158val [32] but this marker was also not associ-
ated with bipolar disorder in 52 affected offspring trios
[27].
Brain-derived neurotrophic factor (BDNF) supports sur-
vival of central nervous system neurons and stimulates
growth and differentiation of developing neurons [33]. A
polymorphism producing an amino acid substitution
(valine to methionine) at codon 66 of the BDNF gene may
impact intracellular trafficking and activity-dependent
secretion of BDNF [34]. Geller et al [28] observed a signif-
icant over-transmission of the Val66 allele in 53 affected
offspring trios of children with pediatric bipolar disorder.
The glutamate decarboxylase 1 gene (GAD1) is expressed
in the brain and codes GAD67 which catalyzes the decar-
boxylation of glutamate to GABA [35,36]. Geller et al [29]
examined the association with a SNP (rs2241165) that
tags an over-transmitted haplotype of GAD1 associated
with childhood schizophrenia [37] and found that the A
allele was also significantly associated with pediatric bipo-
lar disorder.
The dopamine transporter (DAT) plays a central role in
regulation of dopaminergic neurotransmission via
reuptake of synaptic dopamine [38,39]. We previously
conducted a family-based association study of dopamine
transporter gene (SLC6A3) in 170 affected offspring trios
defined by a child (12.9 ± 5.3 years of age) with DSM-IV
Bipolar-I disorder and found a positive association with
one HapMap SNP (rs40184) that survived correction for
multiple statistical comparisons (p = 0.038) [40].
In the current report we test for association with the BDNF
(Val66Met), COMT (Val158Met), and SLC6A4 (HTTLPR)
genes in these families in an attempt to replicate the find-
ings previously reported by Geller et al [26-28]. We were
not aware of the association with GAD1 [29] when candi-
dates were being genotyped so cannot report results for
that gene. We expected to find over-transmission of the
BDNF val66 allele but no evidence of association with
makers in either COMT or SLC6A4.
Methods
Bipolar-I affected offspring triads (N = 173) were drawn
from 522 individuals with 2 parents in 332 nuclear fami-
lies recruited for genetic studies of pediatric psychopathol-
ogy at the Clinical and Research Program in Pediatric
Psychopharmacology and Adult ADHD at Massachusetts
General Hospital [41-44]. All studies were sampled from
the same source population and used the same assess-
ment methodology regardless of the disorder used to clas-
sify subjects as cases. All study procedures were reviewed
and approved by the Partners Healthcare Human
Research Committee. All subjects' parents or guardians
signed written informed consent forms and children older
than 7 years of age signed written assent forms.
All affected offspring in the current analysis were diag-
nosed with bipolar I disorder according to DSM-IV crite-
ria. The DSM-IV requires subjects to meet criterion A for a
distinct period of extreme and persistently elevated,
expansive or irritable mood lasting at least one week, plus
criterion B, manifested by three (four if the mood is irrita-
ble only) of seven symptoms during the period of moodBMC Psychiatry 2009, 9:2 http://www.biomedcentral.com/1471-244X/9/2
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disturbance. Also recorded was the onset of first episode,
the number of episodes, offset of last episode, and total
duration of illness. Psychiatric assessments of child family
members were made with the KSADSE (Epidemiologic
Version) [45] and assessments of adult family members
were made with the Structured Clinical Interview for
DSM-IV [46]. Diagnoses were based on independent
interviews with mothers and direct interviews with the
children older than 12 years of age. Data were combined
such that endorsement by either reporter resulted in a pos-
itive diagnosis. A committee of three psychiatrists, each
board certified in both child and adult psychiatry,
resolved all diagnostic uncertainties. The committee
members were blind to the subjects' ascertainment group,
ascertainment site, and data collected from family mem-
bers.
All genotyping was conducted at the Psychiatric and Neu-
rodevelopmental Genetics Unit of the Massachusetts Gen-
eral Hospital. Lab technicians were not aware of the
source of the samples and all genotyping was performed
in duplicate. The genotyping for SNPs in COMT (rs4680)
and BDNF (rs6265) was performed using a single base
extension reaction with allele discrimination by MassAr-
ray mass spectrometry system (Bruker-Sequenom) as pre-
viously described [47]. Genotyping of the SLC6A4
promoter (5-HTTLPR) polymorphisms was performed
using the following protocol. Genomic DNA (5 ng) was
amplified in a 7 μl reaction using KlenTaq DNA Polymer-
ase (0.2 U), the proprietary KlenTaq Buffer (1×), dNTPs
(200 μM each), 5% glycerol, Betaine (1 M) and the marker
specific primers (0.2 μM). The SLC6A4 promoter VNTR
primers were as follows: SLC6A4_PRO-F 6FAM-
ATGCCAGCACCTAACCCCTAATGT, SLC6A4_PRO-R
GGACCGCAAGGTGGGCGGGA. Amplification was per-
formed with the following protocol: thirteen cycles of
denaturation for 30 seconds at 93°C, annealing for 30
seconds beginning at 61.5°C and dropped 0.5°C every
cycle and primer extension at 72°C for 30 second; 37
cycles of denaturation for 30 seconds at 93°C, annealing
for 30 seconds at 55°C and primer extension at 72°C for
30; 72°C for 1 hour. Amplified products were pooled and
combined with size standard (LIZ-250) before being ana-
lyzed on an ABI-3730. GeneMapper v3.5 was used to ana-
lyze the raw results from the ABI3730, however, a
genotype was not considered final until two laboratory
personnel had independently checked (and corrected) the
GeneMapper results and both individuals were in agree-
ment.
For the Transmission Disequilibrium Test (TDT) we used
the PLINK (v1.0) software package [48]. Findings were
considered statistically significant at p < 0.05.
Results
Bipolar offspring were 12.8 ± 5.2 years old at assessment
and predominantly male (74%, N = 127). As described
above, all children met criteria for DSM-IV bipolar I disor-
der. The mean age at onset was 7.5 ± 4.7 years of age and
the clinical presentation was chronic (3.5 ± 3.8 years dura-
tion), with rapid cycling (22.4 ± 82.3 episodes), and func-
tional impairment (GAF score of 41.0 ± 6.1).
"Risk" alleles, designated to coincide with the previous
reports of Geller et al, were in Hardy-Weinberg equilib-
rium for each gene assessed: BDNF  (Val66, HWE p =
0.99), COMT (COMT-l allele, HWE p = 0.91), and SLC6A4
(HTTLPR short allele, HWE p = 0.72). Allele frequencies
and association results are presented in Table 1. Seventy-
six parents were heterozygous for the BDNF Val66 allele,
142 parents were heterozygous for the COMT-l allele, and
146 parents were heterozygous for the SLC6A4 short
allele. We failed to identify significant associations with
any of these candidates.
Discussion
In this relatively large sample of families with a child
proband diagnosed with DSM-IV bipolar-I disorder, we
replicated earlier reports of no association with the disor-
der and COMT and SLC6A4 (SERT) [26,27]. We did not
replicate the prior association with BDNF [28]. Geller et al
reported a statistically significant (FBAT p-value 0.014)
association in which the Val66 allele was transmitted 21
times and not transmitted 9 times (OR = 2.3, 95% CI =
1.09–4.98). We should have been able to detect an associ-
ation of the magnitude observed in Geller et al [28]: the
power to detect an odds ratio of 2.5 in our data was 0.89
at p < 0.05. If we pool the number of transmitted and not
transmitted alleles in our data with that of Geller et al
[28], the original estimate of association is attenuated and
Table 1: TDT Analysis of candidate genes for pediatric bipolar disorder
Gene Marker Allele1 Frequency T:U2 OR 95% CI χ2
(1) p-value
BDNF Val66Met Val66 0.85 43:35 1.23 0.79–1.92 0.8 0.37
COMT Val158Met COMT-l 0.50 85:67 1.27 0.92–1.75 2.1 0.14
SLC6A4 HTTLPR Short 0.46 73:84 0.87 0.63–1.19 0.8 0.38
T:U (trasmitted:untransmitted counts from basic TDT); OR 95% CI (odds ratio and 95% confidence interval from basic TDT. 1 Val66 (G allele at 
rs6265), COMT-L (Met158; A allele at rs4680), Short (14-repeat allele). 2 76 parents were heterozygous for the BDNF Val66 allele, 142 parents 
were heterozygous for the COMT-l allele, and 146 parents were heterozygous for the SLC6A4 short allele.BMC Psychiatry 2009, 9:2 http://www.biomedcentral.com/1471-244X/9/2
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no longer statistically significant (OR = 1.45, 95% CI =
0.99–2.1, p = 0.1). Of course, a study of 170 families is
modest for genetic association studies and the sample size
needed to detect an odds ratio of 1.5 at p < 0.05 is 562
trios.
Despite the lack of replication observed in our data, BDNF
may continue to be an interesting candidate gene for pedi-
atric bipolar disorder. Although it was not found to be
associated with bipolar disorder in genome-wide associa-
tion studies of the disorder [49-52], Sklar et al [47] found
association with BDNF in a large candidate gene family
study of adults with bipolar disorder. Although prelimi-
nary, a recent study suggests that decreased BDNF gene
expression may play a role in the pathophysiology of
bipolar disorder in children. Pandey et al. [53] observed
significantly lower BDNF mRNA levels in lymphocytes of
children with bipolar disorder compared to healthy con-
trol children. Furthermore, treatment with mood stabiliz-
ers normalized BDNF mRNA level at 8 weeks and change
in symptoms of bipolar disorder was correlated with
change in BDNF mRNA levels [53].
Our results should be interpreted in the context of meth-
odological limitations. In an effort to replicate the extant
literature we focused on single markers that do not cover
the entire region of each gene. Although the power to
detect large genetic effects was acceptable, it was quite low
for smaller, more realistic, effect sizes. Thus, variation
across the entire gene in samples of children large enough
to detect small effects have yet to be conducted. Studies
aimed at better understanding these associations and test-
ing new candidate genes arising from the recent genome
wide association studies are needed. Because the sample
sizes available at independent sites are lacking, the crea-
tion of a viable and collaborative pediatric bipolar disor-
der genetics network will be critical to the success of these
replication studies
Conclusion
Our study suggests that markers examined thus far in
COMT  and  SLC6A4  are not associated with pediatric
bipolar disorder and that if the val66met marker in BDNF
is associated with pediatric bipolar disorder the magni-
tude of the association is much smaller than first reported.
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